Zucara Overview

  • Founded
  • 2015
Founded
  • Status
  • Private
  • Employees
  • 10
Employees
  • Latest Deal Type
  • Series A
  • Latest Deal Amount
  • $21M
Latest Deal Amount
  • Investors
  • 8

Zucara General Information

Description

Developer of a novel drug therapy designed to prevent hypoglycemia in people with diabetes. The company's drug therapy is delivered as a once-daily subcutaneous injection, which will benefit patients by addressing the significant morbidity and mortality associated with hypoglycemia, enabling healthcare providers to change diabetes disease management and improve both patient health and quality of life.

Contact Information

Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 1300-661 University Avenue
  • Toronto, Ontario M5G 0B7
  • Canada

Zucara Timeline

2018201920202021
Financing RoundFinancing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Zucara Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Early Stage VC (Series A) 31-Mar-2020 $21M 000.00 Completed Clinical Trials - Phase 1
7. Grant 12-Jul-2019 0000 00.000 Completed Pre-Clinical Trials
6. Debt - General 09-Apr-2018 00.00 00.000 Completed Pre-Clinical Trials
5. Accelerator/Incubator 09-Feb-2018 00000 Completed Pre-Clinical Trials
4. Grant 08-Feb-2018 00000 00000 Completed Pre-Clinical Trials
3. Grant 21-Sep-2017 00000 Completed Pre-Clinical Trials
2. Early Stage VC (Series A) 03-Nov-2016 Cancelled Startup
1. Early Stage VC 03-Nov-2016 $525K $525K Completed Startup
To view Zucara’s complete valuation and funding history, request access »

Zucara Executive Team (6)

Name Title Board Seat Contact Info
Michael Midmer Co-Founder, Chief Executive Officer & Board Member
Richard Liggins Ph.D Co-Founder and Chief Scientific Officer
Michael Riddell Ph.D Co-Founder & Chairman of Clinical Advisory Board
David Coy Ph.D Advisor
Mladen Vranic Ph.D Advisor
You’re viewing 5 of 6 executive team members. Get the full list »

Zucara Board Members (9)

Name Representing Role Since
Christopher Garabedian Self Board Member 000 0000
Claude Piche Ph.D Zucara Chairman 000 0000
Frederick Callori Self Board Member 000 0000
Luc Mainville Self Chairman 000 0000
Michael Martin Zucara Board Member 000 0000
You’re viewing 5 of 9 board members. Get the full list »

Zucara Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Zucara Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Perceptive Advisors Hedge Fund Minority 000 0000 000000 0
Xontogeny Accelerator/Incubator Minority 000 0000 000000 0
GlycoNet Other 000 0000 000000 0
JLABS Accelerator/Incubator Minority 000 0000 000000 0
National Research Council Canada Government 000 0000 000000 0
You’re viewing 5 of 8 investors. Get the full list »